Скачать с ютуб Trials in Neoadjuvant Therapy for Patients with High-Risk Localized Prostate Cancer в хорошем качестве

Trials in Neoadjuvant Therapy for Patients with High-Risk Localized Prostate Cancer

For the in-depth follow-up Q&A, view this post on Grand Rounds in Urology: https://grandroundsinurology.com/tria... Rana R. McKay, MD, Associate Professor of Medicine at the University of California, San Diego, and Co-Leader of the Genitourinary Oncology Disease Team at the Moores Cancer Center, discusses neoadjuvant hormonal therapy for patients with high-risk localized prostate cancer. Neoadjuvant therapy has been shown to be beneficial to patients with breast, rectal, bladder, and other cancers, but historic neoadjuvant trials in prostate cancer have had limited long-term follow-up and have failed to systematically evaluate pathologic response. More recent trials are seeking to remedy these gaps, and results from a recent phase 2 trial indicate that a subset of high-risk patients do benefit greatly from intense neoadjuvant hormonal therapy. Dr. McKay explains that the phase 3 PROTEUS trial, which is currently recruiting, will hopefully allow researchers to better define exceptional responders and non-responders, identify intermediate pathologic endpoints, and figure out how best to integrate imaging and tissue biomarkers to guide neoadjuvant therapy selection for prostate cancer patients.